New Next-Generation GMP Facility

In an effort to keep up with the growing number of CRISPR-based cell and gene therapies, Synthego has introduced a state-of-the-art GMP facility to accelerate clinical translational therapy development.

With 70% of gene-editing trials now being CRISPR-based, challenges such as procuring reliable GMP-grade sgRNA are becoming more prevalent. This next-generation GMP facility provides solutions to persistent struggles transitioning CRISPR therapies into the clinic, the expertise of CRISPR specialists, regulatory support, and a full range of phase-appropriate sgRNA offerings.

Download the brochure below and check out the rest of Synthego's Clinical Resource Collection:

• CRISPR Clinical Trials And Regulatory Approval Of CRISPR Therapy Drugs
• GMP sgRNA Manufacturing For Seamless Transitions From Discovery To Delivery
• CRISPR Cell And Gene Therapies: Key Challenges In Clinical Development